Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

One trade group has already filed a lawsuit to try to reverse the decision. Meanwhile, a similar fight over Novo Nordisk’s wildly popular drugs Ozempic and Wegovy looms. Semaglutide, the active ...

A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Health-care costs are going up and and yet, workers may still not get the coverage they want — particularly when it comes to drugs like Ozempic.

Thermo Fisher Scientific is responsible for helping to produce some of the hottest drugs on the market, including Novo ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Body aches all over or on specific body parts are usually related to inflammation. This article lists causes to help you get ...